Female (69); Male (60)

0 to 4 years (6); 5 to 9 years (4); 10 to 14 years (8); 15 to 19 years (5); 20 to 24 years (22); 25 to 29 years (22); 30 to 34 years (32); 35 to 39 years (30)

Asian (5); Black or African American (3); More Than One Race (4); Native Hawaiian or Other Pacific Islander (2); White (80); Not Reported (33); Unknown (2)

Hispanic or Latino (17); Not Hispanic or Latino (69); Not Reported (43)

Acute Megakaryoblastic Leukaemia (1); Acute Monoblastic And Monocytic Leukaemia (5); Acute Myeloid Leukaemia, NOS (14); Acute Myelomonocytic Leukaemia (6); Acute Promyelocytic Leukaemia with t(15;17)(q22;q12); PML-RARA (8); Acute Undifferentiated Leukaemia (1); AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 (18); AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 (3); AML with Maturation (2); AML with Minimal Differentiation (3); AML with Mutated CEBPA (7); AML with Mutated NPM1 (17); AML with Myelodysplasia-Related Changes (7); AML with t(6;9)(p23;q34); DEK-NUP214 (3); AML with t(8;21)(q22;Q22); RUNX1-RUNX1T1 (9); AML with t(9;11)(p22;Q\q23); MLLT3-MLL (6); AML without Maturation (5); Mixed Phenotype Acute Leukaemia, B/Myeloid, NOS (1); Mixed Phenotype Acute Leukaemia, T/Myeloid, NOS (2); Myeloid Leukaemia Associated with Down Syndrome (2); Myeloid Sarcoma (2); Therapy-Related Myeloid Neoplasms (7)

Not Reported (129)